COMMUNIQUÉS West-GlobeNewswire

Calidi Biotherapeutics Announces Proposed Public Offering

13/11/2024 - 22:33

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]

UPDATE - Canada’s First Precision Health and Longevity Summit 2024: Uniting Global Leaders on November 15-16

13/11/2024 - 22:34

Unlocking the Future of Healthcare: Pioneering Strategies and Global Collaboration to Enhance Longevity and Health Outcomes for All Canadians CALGARY, Alberta, Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Precision Health and [...]

NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially

13/11/2024 - 22:40

Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in [...]

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

12/11/2024 - 22:05

- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing [...]

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

12/11/2024 - 22:05

MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

12/11/2024 - 22:05

- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and [...]

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

12/11/2024 - 22:05

Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete Responses [...]

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

12/11/2024 - 22:05

Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early December 2024 Plans to [...]

Iridex Reports Third Quarter 2024 Financial Results

12/11/2024 - 22:05

MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]

QIAGEN collaborates with McGill University to advance microbiome research

12/11/2024 - 22:05

QIAGEN and McGill University to collaborate on microbiome research projects to generate evidence-based knowledge for medicine and public health // McGill will serve as a beta-testing site for new QIAGEN microbiome [...]

Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

12/11/2024 - 22:05

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12/11/2024 - 22:05

Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers Presented updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose- [...]

Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets

12/11/2024 - 22:05

Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus ™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, [...]

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

12/11/2024 - 22:05

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical [...]

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12/11/2024 - 22:05

Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its [...]

OrthoPediatrics Corp. to Participate in Upcoming Conferences

12/11/2024 - 22:05

WARSAW, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

12/11/2024 - 22:05

CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

12/11/2024 - 22:05

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK ® in autoimmune diseases Initial data for AlloNK ® in autoimmune indications expected [...]

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

12/11/2024 - 22:05

Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform [...]